Donepezil for dementia due to Alzheimer's disease

多奈哌齐 医学 痴呆 竞争对手 塔克林 安慰剂 阿尔茨海默病 不利影响 内科学 随机对照试验 优势比 临床试验 疾病 药理学 乙酰胆碱酯酶 病理 替代医学 化学 生物化学
作者
J Birks,Richard Harvey
出处
期刊:Cochrane Database of Systematic Reviews 被引量:498
标识
DOI:10.1002/14651858.cd001190
摘要

Background Alzheimer's disease is the most common cause of dementia in older people. One of the aims of therapy is to inhibit the breakdown of a chemical neurotransmitter, acetylcholine, by blocking the relevant enzyme. This can be done by a group of chemicals known as cholinesterase inhibitors. However, some (like tacrine) are associated with adverse effects such as hepatotoxicity, but donepezil (E2020, Aricept) is safer. Objectives The objective of this review is to assess whether donepezil improves the well‐being of patients with dementia due to Alzheimer's disease. Search methods The Cochrane Dementia and Cognitive Improvement Group's Specialized Register was searched using the terms 'donepezil', 'E2020' and 'Aricept' on 9 October 2002. This Register contains up‐to‐date records of all major health care databases and many ongoing trial databases. Members of the Donepezil Study Group and Eisai Inc were contacted. Selection criteria All unconfounded, double‐blind, randomized controlled trials in which treatment with donepezil was compared with placebo for patients with mild, moderate or severe dementia due to Alzheimer's disease. Data collection and analysis Data were extracted by one reviewer (JSB ), pooled where appropriate and possible, and the weighted mean differences or Peto odds ratios (95%CI) estimated. Main results Sixteen trials are included, involving 4365 participants. The trials were of 12, 24 or 52 weeks duration in selected patients. Available outcome data cover domains including cognitive function and global clinical state, but data on several important dimensions of outcome are unavailable. For cognition there is a statistically significant improvement for both 5 and 10 mg/day of donepezil at 24 weeks compared with placebo (‐2.02 points on the ADAS‐Cog scale WMD , 95%CI ‐2.77 to ‐1.26, p<0.00001; ‐2.92 points on the ADAS‐Cog scale WMD 95% CI ‐3.74 to ‐2.10, p<0.00001)and for 10 mg/day donepezil compared with placebo at 52 weeks (1.84MMSE points, 95% CI, 0.53 to3.15, p=0.006). The results show some improvement in global clinical state (assessed by an independent clinician) in people treated with 5 and 10 mg/day of donepezil compared with placebo at 12 and 24 weeks. Benefits of treatment were also seen on measures of activities of daily living and behaviour .There were significantly more withdrawals before the end of treatment from the 10 mg/day (but not the 5 mg/day) donepezil group compared with placebo which may have resulted in some overestimation of beneficial changes at 10 mg/day. A variety of adverse effects were recorded, with more incidents of nausea, vomiting, diarrhoea and anorexia in the 10 mg/day group compared with placebo and the 5 mg/day group, but very few patients left a trial as a direct result of the intervention. Authors' conclusions People with mild, moderate or severe dementia due to Alzheimer's disease treated for periods of 12, 24 or 52 weeks with donepezil experienced benefits in cognitive function, activities of daily living and behaviour. Study clinicians rated global clinical state more positively in treated patients, and measured less decline in measures of global disease severity. Although no significant changes were measured on a patient‐rated quality of life scales, the instrument used was crude and possibly unsuited to the task. The additional data now available confirm the findings of the previous issue of this review and extend the evidence for the effectiveness of treatment to at least 52 weeks and to those with severe dementia. More evidence is still needed for the economic efficacy of donepezil, but clinical efficacy is confirmed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
polly完成签到,获得积分20
1秒前
1秒前
迷路的小牛马完成签到,获得积分10
1秒前
顾影自怜发布了新的文献求助10
2秒前
林璇璇完成签到,获得积分10
2秒前
cctv18应助落羽杉杉采纳,获得10
2秒前
笨笨的凡梅完成签到 ,获得积分10
2秒前
璇er发布了新的文献求助10
3秒前
3秒前
3秒前
秋林发布了新的文献求助10
3秒前
4秒前
Akim应助复尔尔采纳,获得10
5秒前
5秒前
6秒前
CipherSage应助黄尔法采纳,获得10
6秒前
xbf发布了新的文献求助30
6秒前
++发布了新的文献求助30
6秒前
一枚研究僧应助Curry采纳,获得50
7秒前
可爱敏敏杨完成签到,获得积分10
7秒前
cctv18应助如意的向彤采纳,获得10
8秒前
山雨完成签到,获得积分10
8秒前
至黎发布了新的文献求助10
8秒前
9秒前
山水之乐发布了新的文献求助10
9秒前
9秒前
10秒前
10秒前
jin完成签到,获得积分10
10秒前
10秒前
hy完成签到 ,获得积分10
12秒前
带头大哥给杳鸢的求助进行了留言
12秒前
CodeCraft应助xzy采纳,获得10
12秒前
13秒前
jl发布了新的文献求助10
13秒前
至黎完成签到,获得积分10
14秒前
infinity完成签到 ,获得积分10
14秒前
葡萄成熟时完成签到 ,获得积分20
14秒前
yyjw完成签到,获得积分10
15秒前
八戒的梦想完成签到,获得积分10
16秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Very-high-order BVD Schemes Using β-variable THINC Method 830
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3247794
求助须知:如何正确求助?哪些是违规求助? 2891053
关于积分的说明 8265876
捐赠科研通 2559283
什么是DOI,文献DOI怎么找? 1388075
科研通“疑难数据库(出版商)”最低求助积分说明 650683
邀请新用户注册赠送积分活动 627577